Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter

Cancer

Volumn 117, Issue 8, 2011, Pages 1721-1730

  Motomura, Kazuya ^a   Natsume, Atsushi ^a   Kishida, Yugo ^a   Higashi, Hiroyuki ^b   Kondo, Yutaka ^c   Nakasu, Yoko ^d   Abe, Tatsuya ^e   Namba, Hiroki ^f   Wakai, Kenji ^a   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FALCO Biosystems   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e OITA UNIVERSITY   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

glioblastoma; IDH1; interferon ; MGMT methylation; temozolomide

Indexed keywords

BETA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOMICS; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUTATIONAL ANALYSIS; NEUROSURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN METHYLATION; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 79951551576     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25637     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. Mar 10 2005; 352 (10): 987-996. (Pubitemid 40349501)
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Mar 10 2005; 352 (10): 997-1003. (Pubitemid 40349502)
3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. Oct 23 2008; 455 (7216): 1061-1068.
4. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. Sep 26 2008; 321 (5897): 1807-1812.
5. Yan H, Bigner DD, Velculescu V, Parsons DW., Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. Dec 15 2009; 69 (24): 9157-9159.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. Feb 19 2009; 360 (8): 765-773.
7. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H., IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. Oct 1 2009; 15 (19): 6002-6007.
8. Kleihues P BP, Collins VP, et al, ed. WHO Classification of Tumours of the Central Nervous System. Lyon: WHO Press; 2000. IARC,ed.
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. Aug 2007; 114 (2): 97-109. (Pubitemid 47103521)
10. Wakabayashi T, Hatano N, Kajita Y, et al. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol. Aug 2000; 49 (1): 57-62.
11. Wakabayashi T, Kayama T, Nishikawa R, et al. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol. Oct 2008; 38 (10): 715-718.
12. Franco-Hernandez C, Martinez-Glez V, Alonso ME, et al. Gene dosage and mutational analyses of EGFR in oligodendrogliomas. Int J Oncol. Jan 2007; 30 (1): 209-215.
13. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P., Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. Sep 2006; 8 (4): 433-443. (Pubitemid 44377925)
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G., Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. Jun 15 2002; 30 (12): e57.
15. Martinez-Glez V, Franco-Hernandez C, Lomas J, et al. Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma. Cancer Genet Cytogenet. Mar 2007; 173 (2): 170-172. (Pubitemid 46281343)
16. Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-aza-2â-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. Jun 1 2008; 122 (11): 2542-2553. (Pubitemid 351590488)
17. Oi S, Natsume A, Ito M, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2â-deoxycytidine in glioma cells. J Neurooncol. Mar 2009; 92 (1): 15-22.
18. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM., p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res. Feb 1 1992; 52 (3): 674-679.
19. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. Oct 2009; 118 (4): 469-474.
20. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. Oct 1 2004; 64 (19): 6892-6899. (Pubitemid 39330996)
21. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. Dec 1 2009; 27 (34): 5743-5750.
22. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. Sep 1 2008; 26 (25): 4189-4199.
23. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. Apr 20 2007; 25 (12): 1470-1475. (Pubitemid 46733073)
24. Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. May 1 2007; 13 (9): 2606-2613. (Pubitemid 46788026)
25. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. Nov 9 2000; 343 (19): 1350-1354.
26. Ruano Y, Ribalta T, de Lope AR, et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol. Feb 2009; 131 (2): 257-263.
27. Waldman YY, Tuller T, Sharan R, Ruppin E., TP53 cancerous mutations exhibit selection for translation efficiency. Cancer Res. Nov 15 2009; 69 (22): 8807-8813.
28. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. Dec 2007; 6 (12): 975-990. (Pubitemid 350201788)
29. Natsume A, Ishii D, Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. Sep 1 2005; 65 (17): 7573-7579. (Pubitemid 41297227)
30. Natsume A, Wakabayashi T, Ishii D, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol. Apr 2008; 61 (4): 653-659.